Citigroup’s Apollo Endosurgery, Inc. APEN Stock Holding History

Citigroup’s Portfolio APEN Stock Details APEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,000,000	Closed	-$19.8M	–	5896
2023 Q1	$19.8M	Sell	2,000,000 -386,557	-16%	-$3.83M	0.01%	834
2022 Q4	$23.8M	Buy	2,386,557 +376,119	+19%	+$2.8M	0.02%	721
2022 Q3	$11.1M	Buy	2,010,438 +410,438	+26%	+$2.28M	0.01%	1088
2022 Q2	$5.84M	Buy	1,600,000 +453,985	+40%	+$2.15M	﹤0.01%	1452
2022 Q1	$6.93M	Buy	1,146,015 +1,103,319	+2,584%	+$6.72M	﹤0.01%	1493
2021 Q4	$360K	Buy	+42,696	New	+$373K	﹤0.01%	4011
2016 Q1	–	Hold	0	–	–	–	7869
2015 Q4	–	Hold	0	–	–	–	7956

Citigroup's APEN Position: Q2 2023 in Review

Citigroup sold out of Apollo Endosurgery, Inc. (APEN) in Q2 2023, closing a stake of 2,000,000 shares — an estimated $19.8M sold.

Citigroup first reported a position in APEN in Q4 2021 and held it in 6 quarters. The position peaked at $23.8M in Q4 2022. 0 funds tracked by Wall St. Rank hold APEN as of Q2 2023.

Citigroup reported no remaining Apollo Endosurgery, Inc. position as of Q2 2023 after selling out during the quarter.
Citigroup sold 2,000,000 Apollo Endosurgery, Inc. shares in Q2 2023, an estimated $19.8M.
Citigroup first reported a position in Apollo Endosurgery, Inc. in Q4 2021 and held it in 6 quarters.
Citigroup's Apollo Endosurgery, Inc. position peaked at $23.8M in Q4 2022.
0 funds tracked by Wall St. Rank held Apollo Endosurgery, Inc. as of Q2 2023.

Based on Citigroup's 13F filing for Q2 2023, filed 10 Aug 2023.